UPDATE: JP Morgan Reiterates Neutral Rating, Raises PT on Edwards Lifesciences
Posted on December 05, 2012 at 12:27 PM EST
In a report published Wednesday, JP Morgan & Co. reiterated its Neutral rating on Edwards Lifesciences (NYSE: EW ), and raised its price target from $86.00 to $88.00. JP Morgan noted, “We view TAVR as one of the most exciting opportunities in MedTech over the next decade, with WW sales